Willemieke P M Dijksterhuis1, Rob H A Verhoeven2, Marieke Pape1, Marije Slingerland3, Nadia Haj Mohammad4, Judith de Vos-Geelen5, Laurens V Beerepoot6, Theo van Voorthuizen7, Geert-Jan Creemers8, Valery E P P Lemmens9, Martijn G H van Oijen1, Hanneke W M van Laarhoven10. 1. Amsterdam UMC, University of Amsterdam, Department of Medical Oncology, Cancer Center Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands; Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), PO Box 19079, 3501 DB, Utrecht, the Netherlands. 2. Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), PO Box 19079, 3501 DB, Utrecht, the Netherlands. 3. Department of Medical Oncology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, the Netherlands. 4. Department of Medical Oncology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht University, Utrecht, the Netherlands. 5. Department of Internal Medicine, Division of Medical Oncology, GROW-School for Oncology and Developmental Biology, Maastricht UMC+, P. Debyelaan 25, 6229 HX, Maastricht, the Netherlands. 6. Department of Medical Oncology, Elisabeth-TweeSteden Hospital, PO Box 90151, 5000 LC, Tilburg, the Netherlands. 7. Department of Medical Oncology, Rijnstate Hospital, Wagnerlaan 55, 6815 AD, Arnhem, the Netherlands. 8. Department of Medical Oncology, Catharina Hospital, Michelangelolaan 2, 5623 EFJ, Eindhoven, the Netherlands. 9. Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), PO Box 19079, 3501 DB, Utrecht, the Netherlands; Department of Public Health, Erasmus MC University Medical Centre, Doctor Molewaterplein 40, 3015 GD, Rotterdam, the Netherlands. 10. Amsterdam UMC, University of Amsterdam, Department of Medical Oncology, Cancer Center Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands. Electronic address: h.vanlaarhoven@amsterdamumc.nl.
Abstract
BACKGROUND: Beyond first-line palliative systemic treatment can be beneficial to selected oesophagogastric cancer patients, but experience with its administration may be limited and vary among hospitals. In a population-based study, we analysed the association between hospital systemic treatment volume and administration of beyond first-line treatment in oesophagogastric adenocarcinoma, as well as the effect on overall survival (OS). METHODS: Synchronous metastatic oesophagogastric adenocarcinoma patients (2010-2017) were selected from the Netherlands Cancer Registry. Hospitals were categorised in volumes quartiles. The association between hospital systemic treatment volume and the use of beyond first-line treatment was assessed using trend and multivariable logistic regression analyses. OS was compared between hospitals with high and low beyond first-line treatment administration and treatment strategies using Kaplan-Meier curves with log-rank test and multivariable Cox proportional hazard regression. RESULTS: Beyond first-line treatment was administered in 606 of 2,466 patients who received first-line treatment, and increased from 20% to 31% between 2010 and 2017 (P < 0.001). The lowest hospital volumes were independently associated with lower beyond first-line treatment administration compared to the highest volume (OR 0.62, 95% CI 0.39-0.99; OR 0.67, 95% CI 0.48-0.95). Median OS was higher in all patients treated in hospitals with a high versus low beyond first-line treatment administration (7.9 versus 6.2 months, P < 0.001). Second-line paclitaxel/ramucirumab was administered most frequently and independently associated with longer OS compared to taxane monotherapy (HR 0.74, 95% CI 0.59-0.92). CONCLUSION: Higher hospital volume was associated with increased beyond first-line treatment administration in oesophagogastric adenocarcinoma. Second-line paclitaxel/ramucirumab resulted in longer survival compared to taxane monotherapy.
BACKGROUND: Beyond first-line palliative systemic treatment can be beneficial to selected oesophagogastric cancerpatients, but experience with its administration may be limited and vary among hospitals. In a population-based study, we analysed the association between hospital systemic treatment volume and administration of beyond first-line treatment in oesophagogastric adenocarcinoma, as well as the effect on overall survival (OS). METHODS: Synchronous metastatic oesophagogastric adenocarcinomapatients (2010-2017) were selected from the Netherlands Cancer Registry. Hospitals were categorised in volumes quartiles. The association between hospital systemic treatment volume and the use of beyond first-line treatment was assessed using trend and multivariable logistic regression analyses. OS was compared between hospitals with high and low beyond first-line treatment administration and treatment strategies using Kaplan-Meier curves with log-rank test and multivariable Cox proportional hazard regression. RESULTS: Beyond first-line treatment was administered in 606 of 2,466 patients who received first-line treatment, and increased from 20% to 31% between 2010 and 2017 (P < 0.001). The lowest hospital volumes were independently associated with lower beyond first-line treatment administration compared to the highest volume (OR 0.62, 95% CI 0.39-0.99; OR 0.67, 95% CI 0.48-0.95). Median OS was higher in all patients treated in hospitals with a high versus low beyond first-line treatment administration (7.9 versus 6.2 months, P < 0.001). Second-line paclitaxel/ramucirumab was administered most frequently and independently associated with longer OS compared to taxane monotherapy (HR 0.74, 95% CI 0.59-0.92). CONCLUSION: Higher hospital volume was associated with increased beyond first-line treatment administration in oesophagogastric adenocarcinoma. Second-line paclitaxel/ramucirumab resulted in longer survival compared to taxane monotherapy.
Authors: Marieke Pape; Pauline A J Vissers; David Bertwistle; Laura McDonald; Marije Slingerland; Nadia Haj Mohammad; Laurens V Beerepoot; Jelle P Ruurda; Grard A P Nieuwenhuijzen; Paul M Jeene; Hanneke W M van Laarhoven; Rob H A Verhoeven Journal: Ther Adv Med Oncol Date: 2022-03-24 Impact factor: 8.168
Authors: Michael LaPelusa; Chan Shen; Erin A Gillaspie; Christopher Cann; Eric Lambright; A Bapsi Chakravarthy; Michael K Gibson; Cathy Eng Journal: Cancers (Basel) Date: 2022-07-26 Impact factor: 6.575
Authors: Willemieke P M Dijksterhuis; Marianne C Kalff; Anna D Wagner; Rob H A Verhoeven; Valery E P P Lemmens; Martijn G H van Oijen; Suzanne S Gisbertz; Mark I van Berge Henegouwen; Hanneke W M van Laarhoven Journal: J Natl Cancer Inst Date: 2021-11-02 Impact factor: 13.506